Clik here to view.
NICE’s Social Value Judgments: A Closer Look at Progress
Koonal Shah Now out as a “FirstView” article in Health Economics, Policy and Law [1] is an important analysis on the inclusion of social value judgments in NICE guidance, co-authored by OHE’s Koonal...
View ArticleClik here to view.
HTAinSite: Recent Changes in the Database of NICE Decisions
Imagine being able to find, in ONE minute or less, which NICE Technology Assessments (TAs) make specific reference to QALY thresholds of £20,000 or £30,000, for example, or to risk sharing, or patient...
View ArticleClik here to view.
New Findings: Public Attitudes Towards End-of-Life Treatment in England and...
Koonal Shah In 2009, the UK’s National Institute for Health and Clinical Excellence (NICE) issued supplementary advice that its Appraisal Committees are to consider when assessing treatments that...
View ArticleSpotlight on OHE: Value Based Pricing and New Technologies
The OHE has been very active in conceptualising approaches incorporating a broader assessment of the elements of value (often called “value based pricing” or “VBP”), as its publications to date...
View ArticleClik here to view.
New OHE Study Compares Decisions by Five HTA Agencies on Oncology Meds
Just out in the International Journal of Technology Assessment in Health Care is an important new study that reviews appraisals of breast cancer and colorectal cancer medicines by HTA agencies in a...
View ArticleClik here to view.
OHE Presents at Two Key Workshops on Use of EQ-5D in HTA Across Asia
OHE’s Prof Nancy Devlin presented at two key workshops held for researchers and HTA policy makers from across Asia. The workshops were organised by Prof Nan Luo, National University of Singapore, in...
View ArticleNICE Decisions: Exploring the Influence of Cost-Effectiveness and Other Factors
OHE presents a series of lunchtime seminars throughout the year. The most recent seminar, held in late April, considered the influence of cost-effectiveness and other factors on NICE decisions. Led by...
View ArticleClik here to view.
NICE Decisions: Cost-effectiveness Is the Most Significant Predictor
Established in 1999, the National Institute for Health and Care Excellence (NICE) undertakes appraisals of selected technologies and issues guidance intended to ensure quality and value for money. Its...
View ArticleClik here to view.
Critique of Research Proposing to Lower NICE’s Cost-per-QALY Threshold to...
The OHE has just published an Occasional Paper[1] by Barnsley et al that counters the recently-published recommendation by Claxton et al[2] that NICE should lower its cost-per-QALY threshold from the...
View ArticleClik here to view.
OHE Consulting Offers New Services in Patient-Reported Outcomes
OHE Consulting is now offering our clients advice and analytical services on health outcomes and the use of patient-reported outcomes (PRO) data, building on the extensive programme of original...
View ArticleSocial Preferences and Burden of Illness in Value-based Assessments
Throughout the year, OHE presents a number of Lunchtime Seminars intended to discuss important current issues in health economics. On 30 January, OHE invited Dr Donna Rowen of the University of...
View ArticleClik here to view.
Implementing NICE Decisions in Wales: Opportunity Costs
Just out is a new Research Paper from OHE that examines how local NHS organisations in Wales adjust spending to accommodate ‘shocks’ such as new NICE mandates for covering specific technologies. By...
View ArticleSpotlight on OHE: NICE, Biosimilars, HTA
OHE’s active involvement in a number of recent conferences and meetings has contributed to discussions on a range of important issue in health economics. Changes in NICE decision making The...
View Article
